COMPARE · Data as of August 21, 2026

BSX vs PODD

Verdict: Side-by-side breakdown using the Bull Rankings model. BSX scored 78.1, PODD scored 77.6 — BSX leads.
Compare another set
BSX
Boston Scientific Corporation
Medical Devices · Quality-Growth
78.1
$50.37 · $73.0B
fundamentals as of
Score gap
0.5
BSX leads
PODD
Insulet Corporation
Medical Devices · Quality-Growth
77.6
$148.16 · $10.3B
fundamentals as of
  • CheapestBSX20.4x
  • Fastest growthPODD+29.4%
  • Strongest balance sheetBSX0.50
  • Highest qualityPODD73 / 100
  • Largest discount to fair valueBSX-12%
THE BULL RANKINGS SCORECARD78.1/ 100 · BULL SCOREPEER MEDIANQUALITY71.2GROWTH88.4VALUE75.8
THE BULL RANKINGS SCORECARD77.6/ 100 · BULL SCOREPEER MEDIANQUALITY73.3GROWTH95.3VALUE66.7
BSXPODDQuality71.273.3Growth88.495.3Value75.866.7
cheap & fastrevenue growth →← cheaper (lower multiple)4%39%15x33xBSXPODD

Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.

FCFBSX$3.6bPODD$294m
RevBSX+13.5%PODD+29.4%
D/EBSX0.50PODD0.67
P/EBSX20.4xPODD27.8x
PEGBSX0.75PODD1.52
BSX
stronger →← stronger
PODD
71
Qualityreturns · margins · balance sheet
73
88
Growthrevenue & earnings expansion
95
76
Valuevaluation vs sector peers
67
PODD is stronger on 2 of 3 pillars.
BSX
PODD
$3.6bB
FCF
$294mC
+13.5%B+
Rev
+29.4%A-
0.50B
D/E
0.67C+
20.4xB+
P/E
27.8xB
0.75A-
PEG
1.52C+
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
BSX
PODD
12% below
Price vs fair valuelower is cheaper
83% above
~1%/yr
Growth the price implies10-yr FCF · lower = less priced in
~27%/yr
+12%
1-yr DCF upside
-55%
+14%
5-yr DCF upside
-45%
+16%
10-yr DCF upside
-27%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
BSX
Why this score
  • Buying back stock
PODD
No notable signals flagged.
BSXBoston Scientific Corporation
Medical Devices · $50.37 · beta 0.57
Why now
Medical Devices · market cap $73.0b. Down 54% from 52-week high of $109.50 — deep drawdown territory. Revenue growing +14%, comfortably above the S&P median. PEG 0.75 — paying under fair value for the growth rate. 29 sell-side analysts rate this a Buy with a mean 1-yr target of $62.69 (implying +24% upside).
Moat
Net margin 17% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 15% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 99% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Down 54% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
PODDInsulet Corporation
Medical Devices · $148.16 · beta 1.09
Why now
Medical Devices · market cap $10.3b. Down 58% from 52-week high of $354.88 — deep drawdown territory. Revenue growing +29% — in hypergrowth territory. 22 sell-side analysts rate this a Buy with a mean 1-yr target of $171.91 (implying +16% upside).
Moat
Net margin 12% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 26% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk
Down 58% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.

Where BSX and PODD diverge

On the headline score the gap is 0.5 points in favor of BSX. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.

Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.